We are developing a potential drug candidate APN01* (alunacedase alfa), based on our proprietary ACE2 platform to address the growing global health threat of COVID-19. APN01 is ideally suited to prevent the infection with SARS-CoV-2, reduce injury to multiple organs and mitigate the deleterious consequences of established viral infection. ACE2, and its role in respiratory...